Staph infection vaccine trial cut short
The vaccine - V710 - was studied in approximately 8,000 patients in 26 countries as part of a double-blind, randomized, placebo-controlled trial. The vaccine was previously shown to work well in animals and a single dose in human volunteers produced the intended antibodies, the Los Angeles Times reports.
The clinical trial of V710 was halted ahead of schedule after safety monitors found that the vaccine failed to protect patients under real-world conditions better than the placebo.
According to the study, which was published by the Journal of the American Medical Association, staph infections in the study occurred at a rate of 2.6 cases per 100 person-years in patients taking the vaccine and 3.2 cases per 100 person-years in patients receiving the placebo, the Los Angeles Times reports.
The study is one of several that has shown promise in early tests only to fall short in later clinical trials. A staph vaccine tested in kidney patient on hemodialysis also suffered a similar fate.
"The paradoxical finding of worse outcomes after receipt of a vaccine has been previously encountered," the study authors said, according to the Los Angeles Times.